Rairigh joins as Executive Vice President of Corporate Development to bolster Psilera's business and commercial strategies

TAMPA, Fla., Sept. 4, 2025 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for complex neurological disorders, has appointed Scott W. Rairigh as Executive Vice President of Corporate Development. In this capacity, Rairigh will oversee business development, investor relations, and commercialization strategies as the company moves its medicines closer to the clinic.

"Scott's energy and passion for drug development makes him a perfect addition to our Executive Leadership Team," said Dr. Chris Witowski, CEO of Psilera. "He is a dynamic and thoughtful leader whose addition to the team has served as a catalyst to further our innovative neuroplastogen pipeline. His robust experience will help advance our mission to deliver medicines that change the way the world thinks."

Rairigh joins Psilera from Celgene and Bristol Myers Squibb where he most recently served as Global Commercial Lead for Precision Medicine initiatives in Oncology, Hematology, and Neuroscience. Prior to this, Rairigh spent 17 years at Johnson & Johnson in leadership positions across the Pharmaceutical and Diagnostic segments where he delivered personalized medicine solutions in several therapeutic areas which included brain health with a focus on Alzheimer's disease and depression. Rairigh's career was formed from the foundation of a Bachelor of Science degree from Towson University and a Master of Science degree from Johns Hopkins University as well as a Leadership Certificate from the Harvard Business School.

"This expanded role with Psilera allows me to serve patients and families more meaningfully," said Rairigh. "Since joining the Board in 2019, I have been thoroughly impressed by Dr. von Salm, Dr. Witowski, and the entire Psilera team. Their commitment to delivering first-in-class medicines that rewire and activate neuronal pathways targeting dementia, addiction, and other brain health challenges is extraordinary."

About Psilera:

Psilera is a biotech research and development company founded to create medicines that change the way the world thinks. By harnessing the potential of natural products, the company advances neuroplastic therapies to help patients suffering from neurodegeneration and addiction. Psilera has amassed a leading pipeline of next-generation assets including PSIL-006, a first-in-class therapeutic for the treatment of frontotemporal dementia (FTD). To learn more about this new era in mindful medicine visit www.psilera.com.

Media Contact:

Psilera Inc.
Michael Lauer
MDL Strategic Communications
michael@mdlcomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-industry-veteran-scott-rairigh-joins-psilera-to-lead-corporate-development-302546005.html

SOURCE Psilera, Inc.